Graul-Conroy Amanda, Hoover-Regan Margo, DeSantes Kenneth B, Sondel Paul M, Callander Natalie S, Longo Walter L, Fahl William E
Department of Pediatrics, Hematology-Oncology Program, University of Wisconsin-Madison, USA.
Department of Pediatrics, Hematology-Oncology Program, Baylor College of Medicine, USA.
Integr Cancer Sci Ther. 2018 Dec;5(6). doi: 10.15761/ICST.1000293. Epub 2018 Nov 29.
Grade 3 oral mucositis (OM) is historically observed in >90% of bone marrow transplant patients who received the cyclophosphamide + total body irradiation (CY+TBI) conditioning regimen. It was previously shown that orotopically applied adrenergic vasoconstrictor prevented up to 100% of radiation-induced oral mucositis in two preclinical animal models.
drenergic vasoconstrictor (i.e., phenylephrine in an aqueous-alcohol NG11-1 formulation) was orotopically applied to three patients (ages 24-29) who received the CY+TBI conditioning regimen; they were compared to five matched controls who received no orotopical vasoconstrictor. All patients received the CY+TBI conditioning regimen for acute lymphoblastic leukemia within the University of Wisconsin Adult Bone Marrow Transplant Program. Over the seven-day Cy+TBI conditioning regimen, 20 min before each treatment, either radiation or chemotherapy, vasoconstrictor was applied topically to the oral cavity, and patients then received either 1.5 Gy whole-body radiation or IV cyclophosphamide.
OM severity was scored over a three-week period using: i) physican assessments, ii) daily photos of the oral cavity, iii) oral pain and oral function score sheets, and iv) recorded narcotic consumption. Both "Grade 3 OM" duration and "any OM" duration in vasoconstrictor-treated patients were substantially lower than for the five control patients. Though nasogastric tube or total parenteral nutrition were used in 3 out of 5 control patients, there was no use of these supportive care measures in the three vasoconstrictor-treated patients.
Orotopically applied NG11-1 vasoconstrictor formulation substantially reduced the incidence and severity of "Grade 3" and "any" oral mucositis when compared to matched control patients, all of whom received the same CY+TBI conditioning regimen. The liquid orotopical formulation was easily tolerated by patients both in its ease of use and lack of side effects.
从历史数据来看,在接受环磷酰胺+全身照射(CY+TBI)预处理方案的骨髓移植患者中,超过90%会出现3级口腔黏膜炎(OM)。此前在两个临床前动物模型中已表明,口腔局部应用肾上腺素能血管收缩剂可预防高达100%的放射性口腔黏膜炎。
将肾上腺素能血管收缩剂(即苯肾上腺素的水 - 醇NG11 - 1制剂)局部应用于3例(年龄24 - 29岁)接受CY+TBI预处理方案的患者;将他们与5例未接受口腔局部血管收缩剂的匹配对照患者进行比较。所有患者均在威斯康星大学成人骨髓移植项目中接受CY+TBI预处理方案用于急性淋巴细胞白血病治疗。在为期7天的CY+TBI预处理方案期间,每次治疗(放疗或化疗)前20分钟,将血管收缩剂局部应用于口腔,然后患者接受1.5 Gy全身照射或静脉注射环磷酰胺。
在三周时间内,通过以下方式对OM严重程度进行评分:i)医生评估,ii)口腔每日照片,iii)口腔疼痛和口腔功能评分表,以及iv)记录的麻醉剂消耗量。血管收缩剂治疗患者的“3级OM”持续时间和“任何OM”持续时间均显著低于5例对照患者。虽然5例对照患者中有3例使用了鼻胃管或全胃肠外营养,但3例血管收缩剂治疗患者未使用这些支持性护理措施。
与匹配的对照患者相比,局部应用NG11 - 1血管收缩剂制剂显著降低了“3级”和“任何”口腔黏膜炎的发生率和严重程度,所有对照患者均接受相同的CY+TBI预处理方案。这种液体口腔局部制剂使用方便且无副作用,患者易于耐受。